

Guideline adaptation of fidaxomicin as first-line therapy for *Clostridioides difficile* infection in institutions across the United States

Angela Basir, PharmD Candidate 2023, Nicole Bradley, PharmD, BCPS, BCIDP, Yuman (Yumi) Lee, PharmD, BCIDP, AAHIVP
St. John's University College of Pharmacy and Health Sciences, Queens, NY

Introduction

- In 2021, *Clostridioides difficile* infection (CDI) treatment guidelines were updated to recommend fidaxomicin over vancomycin as first-line therapy in initial and recurrent CDI
- Prior to this, fidaxomicin use was limited as cheaper alternatives were recommended as first line therapy

Objectives

- To assess the guideline adaptation of fidaxomicin as first-line therapy in CDI management in institutions across the United States (US)
- To identify barriers to fidaxomicin use


Methods

- 13-item electronic survey was created to assess guideline adaptation of fidaxomicin
- Baseline demographics, current practices and barriers to fidaxomicin use were collected
- Distributed to members of the American Society of Health-System Pharmacists in April 2022
- Participation was voluntary and anonymous
- Results analyzed using descriptive statistics
- Fisher's Exact Tests used to compare categorical data
- IRB approval obtained from St. John's University

Results

Table 1: Baseline Demographics (N=63)

Institution Type (%)	Large Academic Medical Center	28.6
	Community Hospital (non-teaching)	42.9
	Community Hospital (teaching)	23.8
	Federal Government Owned	3.2
	Critical Access	1
Region (%)	Northeast	22.2
	Southeast	22.2
	Midwest	33.3
	Southwest	14.3
	West	7.9



Results

Table 2: Survey Responses (N=63)

Did you know that the IDSA now recommends fidaxomicin as 1 st line therapy for CDI? (%),n	
• Yes	44.4 (28)
• No	7.9 (5)
• No response	47.6 (30)
Mean comfort level with using fidaxomicin as 1 st line for CDI (1- extremely uncomfortable, 5- extremely comfortable)	3.4
Institutions with CDI Guidelines (N=48)	
How is fidaxomicin used within your institution? Select all that apply. (%),n	
• 1 st line – non-severe, initial	22 (11)
• 1 st line – severe, initial	18.8 (9)
• 1 st line – recurrence	45.8 (22)
• 1 st line – fulminant	4.2 (2)
• Oral vancomycin is still preferred	54 (26)
Institutions without CDI Guidelines (N=15)	
Is fidaxomicin on formulary? (%),n	
• Yes, available to all prescribers	20 (3)
• Yes, restricted to ID/GI	33.3 (5)
• No	46.7 (7)
Is fidaxomicin used as 1 st line treatment for CDI? (%),n	
• Yes	0 (0)
• No	100 (15)

Figure 2: Number of Barriers to Fidaxomicin Use





Figure 3: Common Barrier to Fidaxomicin Use



Conclusions

- Majority of institutions do not currently recommend use of fidaxomicin as first line therapy for CDI despite the recent guideline updates. Institutions with CDI treatment guidelines were more likely to recommend fidaxomicin as first-line therapy. Cost and lack of formulary availability were identified as the most common barriers to fidaxomicin use.